Physician profile
Peter Formusoh
NPI 1114559325
$5,348.64
in general payments reported to CMS, 2019-2025
13 companies · $3,380 in 2025
The $3,380 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $343 · 2024: $1,476 · 2025: $3,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,083 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,082.59 |
| Education | $116.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,482.49 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,139.83 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $546.76 | 2022-2025 | Caplyta |
| Abbvie INC. | $539.92 | 2024-2025 | |
| Alkermes, INC. | $325.22 | 2022-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $310.19 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $267.68 | 2025 | Cobenfy |
| Lundbeck LLC | $259.39 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $188.76 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $150.36 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $83.97 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $35.92 | 2025 | |
| Soleno Therapeutics, INC. | $18.15 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Formusoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.